Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable

CRANBURY, N.J., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.


CONTACT: Amicus Therapeutics Chip Baird (609) 662-2063 cbaird@amicusrx.comSource:Amicus Therapeutics, Inc.